Recombinant Rhesus monkey APOBEC3F Protein, His-tagged
Cat.No. : | APOBEC3F-364R |
Product Overview : | Recombinant Rhesus monkey APOBEC3F full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
- Download
Source : | Mammalian Cells |
Species : | Rhesus monkey |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | APOBEC3F apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | APOBEC3F |
Synonyms : | APOBEC3F; DNA dC->dU-editing enzyme APOBEC-3F; apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3F; |
Gene ID : | 723812 |
mRNA Refseq : | NM_001042373 |
Protein Refseq : | NP_001035832 |
MIM : | |
UniProt ID : | Q1G0Z6 |
Products Types
◆ Recombinant Protein | ||
APOBEC3F-147H | Recombinant Human APOBEC3F Protein, His-tagged | +Inquiry |
APOBEC3F-193R | Recombinant Rhesus Macaque APOBEC3F Protein, His (Fc)-Avi-tagged | +Inquiry |
APOBEC3F-700H | Recombinant Human APOBEC3F protein, GST-tagged | +Inquiry |
APOBEC3F-1575H | Recombinant Human APOBEC3F protein | +Inquiry |
◆ Lysates | ||
APOBEC3F-8785HCL | Recombinant Human APOBEC3F 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (17)
Ask a questionThere is ongoing research to explore the potential of targeting APOBEC3F for therapeutic purposes, particularly in the context of HIV-1 infection. By modulating the activity of APOBEC3F, it may be possible to enhance its antiviral effects and inhibit virus replication.
Yes, APOBEC3F activity can be regulated by various cellular factors. For example, the Vif protein encoded by HIV-1 can bind to APOBEC3F and target it for degradation, thereby counteracting its antiviral activity.
APOBEC3F interacts with the viral replication machinery during reverse transcription, the process by which the virus converts its RNA genome into DNA. It binds to the single-stranded viral DNA, where it can deaminate cytosines and induce hypermutation specifically in the viral genome.
Yes, APOBEC3F has the potential to deaminate cytosine residues in cellular DNA as well. However, it is believed that cellular mechanisms and other APOBEC proteins, such as APOBEC3G, work together to limit the damage caused by APOBEC3F to the cellular genome.
APOBEC3F has been shown to play a role in controlling endogenous retroelements, which are remnants of ancient retroviral infections that have become part of the human genome. It helps to suppress the activity of retroelements and prevent their harmful effects.
APOBEC3F is expressed primarily in immune cells, such as T cells, B cells, and macrophages.
While APOBEC3F can be counteracted by the Vif protein of certain viruses like HIV-1, there are no known viruses that can directly counteract APOBEC3F activity without the presence of Vif. However, viruses may have other strategies to evade or counteract APOBEC3F through different mechanisms.
APOBEC3F expression levels have been investigated as potential diagnostic and prognostic markers in certain cancers, such as hepatocellular carcinoma. However, more research is needed to validate its utility in clinical settings.
There have been studies exploring ways to artificially upregulate or enhance APOBEC3F expression to enhance its antiviral activity. For example, researchers have investigated the use of small molecule drugs that can induce APOBEC3F expression to enhance its antiviral effects. However, further research is needed to determine the efficacy and safety of such approaches.
APOBEC3F deaminates cytosine residues in the viral DNA, leading to the conversion of cytosine to uracil. During DNA replication, uracil is recognized as an error and is likely to be replaced by other nucleotides, resulting in the introduction of mutations in the viral genome.
Currently, there are no specific drugs available that can directly modulate APOBEC3F activity. However, some drugs that can affect the overall activity of the APOBEC family of proteins, including APOBEC3F, have been investigated. These drugs target cellular pathways that regulate APOBEC protein expression or function, but their specific effects on APOBEC3F need further exploration.
APOBEC3F and other members of the APOBEC3 family are thought to have evolved as part of an ongoing arms race between retroviruses and host defense mechanisms. The viruses evolved strategies to counteract APOBEC3 proteins, leading to the generation of diverse APOBEC3 variants in the host population.
Yes, there are genetic variations, including single nucleotide polymorphisms (SNPs), identified in the APOBEC3F gene. Some of these variations have been associated with altered susceptibility to viral infections and cancer development.
There are currently no specific therapeutic strategies targeting APOBEC3F directly. However, understanding its function and interaction with viral pathogens could potentially lead to the development of targeted therapies in the future.
Currently, there are no specific inhibitors of APOBEC3F identified. However, research is being conducted to discover small molecules or peptides that can selectively inhibit the activity of APOBEC3F without affecting other important cellular processes.
APOBEC3F dysfunction has been implicated in certain cancers, including liver and lung cancers. Additionally, some studies have suggested that APOBEC3F activity may be involved in immune-related diseases like systemic lupus erythematosus (SLE).
There is ongoing research exploring the potential use of APOBEC3F as a target for gene therapy approaches. Strategies could involve modifying or enhancing APOBEC3F function to enhance antiviral activity or selectively target cancer cells. However, this area of research is still in its early stages and requires further development.
Customer Reviews (4)
Write a reviewThis specificity enables precise quantification and characterization of APOBEC3F and its interactions with other molecules or proteins of interest.
The APOBEC3F protein exhibits a high degree of specificity in various assays, ensuring accurate and reliable results.
Its exceptional performance, coupled with its ability to generate clear and precise protein bands, make it an indispensable tool in achieving accurate and reliable results.
APOBEC3F protein is known for its stability and robustness, making it suitable for a wide range of experimental conditions.
Ask a Question for All APOBEC3F Products
Required fields are marked with *
My Review for All APOBEC3F Products
Required fields are marked with *
Inquiry Basket